الفهرس 
PARATHYROID HORMONEOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
ABSTRACT
Background: Cardiovascular disease is the most common cause of death in patients with end-stage renal disease (ESRD) and accounts for much of the morbidity in this population.
Aim of the Work: We therefore aimed to consider the evidences regarding the role of excess PTH in the development of left ventricular (LV) hypertrophy as well as LV ejection fraction in patients with end-stage renal disease under regular hemodialysis.
Patients and Methods: This study was cross sectional study and was conducted in hemodialysis unit, Elsahel Hospital. This study was conducted on 70 patients on regular hemodialysis (3 times a week for at least 6 months) for timing of study from January 2022 to June 2022.
Results: In our study, we demonstrated that there was statistically significant relation between P.T.H quartiles and LVMI which found higher in 2nd quartile and lower in 3rd quartile with p-value = 0.036. Our results showed that there was statistically significant positive correlation found between LVMASS and AP, LVEDD, PWT, IVST and LVMI and also negative correlation between LVMASS and weight, BMI and EF% among female patients.
Conclusion: our study suggested the role of hyperparathyroidism in the development of LVH, with a potential impact on cardiovascular outcome for patients on HD. Adverse effects of secondary hyperparathyroidism on LV function and structure showed the role of excess PTH in the development of left ventricular (LV) hypertrophy as well as low LV ejection fraction in patients with end-stage renal disease under hemodialysis which needs more attention to control of secondary hyperparathyroidism to reduce the risk of cardiovascular morbidity and mortality in dialysis patients.